Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy

Abstract

Although anti-CD38 monoclonal antibodies have improved the prognosis of relapsed/refractory multiple myeloma (RRMM), some patients still experience early relapses with poor outcomes. This present study evaluated the predictive value of FDG PET/CT parameters for RRMM prior to initiating anti-CD38 treatment. We included 38 consecutive RRMM patients who underwent a PET/CT scan treated at our institution at relapse. The median PFS was 12.5 months and the median OS was not reached. 42% of the patients had an initial ISS score of 1, 37% of 2, and 21% of 3. The presence of >3 focal lesions (FLs, n = 19) and the ISS score were associated with inferior PFS (p = 0.0036 and p = 0.0026) and OS (p = 0.025 and p = 0.0098). Patients with >3 FLs had a higher initial ISS score (p = 0.028). In multivariable analysis, the ISS score and >3 FLs were independent prognostic factors for PFS (p = 0.010 and p = 0.025 respectively), and combined they individualized a high-risk group with a median PFS and OS of 3.1 months and 8.5 months respectively vs. not reached for the other patients. The presence of >3 FLs on PET was predictive of survival outcomes in patients with RRMM treated using CD38 targeted therapy. Combined with the initial ISS, an ultra-high-risk RRMM population can thus be identified.

New Developments in Myeloma Treatment and Response Assessment

“…The presence of more than 3 FLs and the Multiple Myeloma International Staging System score were independently associated with inferior PFS and overall survival, allowing the identification of a population with an ultrahigh risk of relapsed or refractory MM (98).…”

“…More recently, a study evaluated the predictive value of 18 F-FDG PET/CT parameters for relapsed or refractory MM before initiating anti-CD38 treatment. The presence of more than 3 FLs and the Multiple Myeloma International Staging System score were independently associated with inferior PFS and overall survival, allowing the identification of a population with an ultrahigh risk of relapsed or refractory MM ( 98 ).…”